Nuveen
CMMB icon

Nuveen’s Chemomab Therapeutics CMMB Stock Holding History

Nuveen’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$378 Buy
+235
New +$482 ﹤0.01% 5000

Other funds holding CMMB

Kestra Private Wealth Services
Kestra Private Wealth Services Austin, Texas $9.37B AUM 22.72% 1-Year Est. Return
StoneX Group
StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return
Philadelphia Investment Partners
Philadelphia Investment Partners Voorhees, New Jersey $163M AUM
SmartHarvest Portfolios
SmartHarvest Portfolios Poulsbo, Washington $258M AUM 39.79% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

Nuveen's CMMB Position: Q3 2026 in Review

Nuveen opened a new position in Chemomab Therapeutics (CMMB) in Q3 2026: 235 shares worth $378. The stake represents ﹤0.01% of the portfolio and ranks #5000 among its holdings.

8 funds tracked by Wall St. Rank hold CMMB as of Q3 2026.

  • Nuveen held 235 shares of Chemomab Therapeutics worth $378 as of Q3 2026.
  • Chemomab Therapeutics was a new Nuveen position in Q3 2026.
  • Chemomab Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #5000 holding.
  • 8 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.